Grifols (GRF) CMD 2025 summary

Strategic vision and growth targets

• Aims to achieve €10 billion revenue by 2029 and €14 billion by 2034, doubling size over the next decade, driven by biopharma growth, innovation, and operational efficiency.

• Projects EBITDA of ~€2.9 billion and a 29–30% margin by 2029, with free cash flow of €1.2 billion and a 40% EBITDA-to-cash conversion rate.

• Strategic plan is bottom-up, realistic, and organization-wide, with a 7% revenue CAGR and 10% EBITDA CAGR from 2024–2029.

• Focuses on disciplined capital allocation, prioritizing organic investment, cost control, and margin expansion, with net leverage targeted at 3–3.5x and dividends reinstated from 2025.

• Vision includes global patient access, sustainability integration, and leadership renewal to reinforce accountability.

Financial performance and guidance

• 2024 delivered record revenues (€7.2 billion, +10.3% cc), EBITDA (+21% adj., +32% reported), and free cash flow outperformance.

• 2025 guidance: revenue of €7.7 billion, adjusted EBITDA of €1.88–2.03 billion, and free cash flow of €350–500 million, with IRA Part D redesign impact of €100–150 million fully embedded.

• Free cash flow conversion to adjusted EBITDA expected to rise from 15% (2024) to 40% (2029), with cumulative FCF generation pre-M&A projected at €3.5–3.75 billion over 2025–2029.

• Leverage reduced from 6.8x to 4.6x in 2024, with a target of 3.0–3.5x by 2029 and significant organic deleveraging capacity.

• Strategic investments in plasma and industrial networks secure cost-effective sourcing and support growth.

Value creation plan, operational improvements, and margin expansion

• Value creation driven by commercial growth (IG, Albumin, Alpha-1, new launches), margin expansion (plasma sourcing mix, collection excellence, yield improvements), and pipeline execution.

• Achieved over €450 million in savings through operational improvements, optimizing cost and cash flow.

• Margin expansion supported by cost per liter reduction, individualized nomogram rollout, and yield optimization, aiming for a 500 bps EBITDA margin increase by 2029.

• CapEx needs are well-defined at €2.5 billion over five years, with CapEx as a percentage of revenue declining from 9% to 5%.

• Working capital investment to normalize at ~3.5% of sales, supporting growth while optimizing inventory.